Mauna Kea Technologies SAS - Asset Resilience Ratio

Latest as of June 2025: 5.24%

Mauna Kea Technologies SAS (ALMKT) has an Asset Resilience Ratio of 5.24% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€663.00K
≈ $775.12K USD Cash + Short-term Investments

Total Assets

€12.66 Million
≈ $14.80 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2024)

This chart shows how Mauna Kea Technologies SAS's Asset Resilience Ratio has changed over time. Check Mauna Kea Technologies SAS (ALMKT) strategic investment index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Mauna Kea Technologies SAS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Mauna Kea Technologies SAS stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €663.00K 5.24%
Short-term Investments €0.00 0%
Total Liquid Assets €663.00K 5.24%

Asset Resilience Insights

  • Limited Liquidity: Mauna Kea Technologies SAS maintains only 5.24% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Mauna Kea Technologies SAS Industry Peers by Asset Resilience Ratio

Compare Mauna Kea Technologies SAS's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
GN Store Nord
CO:GN
Medical Devices -4.56%
Getein Biotech Inc
SHG:603387
Medical Devices 29.77%
Ningbo David Medical Device Co Ltd
SHE:300314
Medical Devices 6.89%
Vieworks Co. Ltd
KQ:100120
Medical Devices 7.81%
Somnomed Ltd
AU:SOM
Medical Devices 24.67%
Dynamic Medical Technologies
TWO:4138
Medical Devices 18.54%
T&R Biofab Co. Ltd
KQ:246710
Medical Devices 0.12%

Annual Asset Resilience Ratio for Mauna Kea Technologies SAS (2011–2024)

The table below shows the annual Asset Resilience Ratio data for Mauna Kea Technologies SAS.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 12.42% €2.02 Million
≈ $2.36 Million
€16.25 Million
≈ $18.99 Million
+12.26pp
2023-12-31 0.16% €36.00K
≈ $42.09K
€22.94 Million
≈ $26.82 Million
+0.11pp
2022-12-31 0.05% €9.00K
≈ $10.52K
€19.79 Million
≈ $23.14 Million
-0.07pp
2021-12-31 0.12% €29.00K
≈ $33.90K
€24.75 Million
≈ $28.94 Million
-0.16pp
2020-12-31 0.28% €58.00K
≈ $67.81K
€20.61 Million
≈ $24.09 Million
+0.03pp
2019-12-31 0.25% €59.00K
≈ $68.98K
€23.62 Million
≈ $27.62 Million
-0.07pp
2018-12-31 0.32% €64.00K
≈ $74.82K
€19.76 Million
≈ $23.10 Million
-0.13pp
2017-12-31 0.45% €125.00K
≈ $146.14K
€27.75 Million
≈ $32.44 Million
-0.02pp
2016-12-31 0.47% €94.00K
≈ $109.90K
€19.97 Million
≈ $23.35 Million
+0.18pp
2015-12-31 0.29% €65.00K
≈ $75.99K
€22.50 Million
≈ $26.31 Million
-0.18pp
2014-12-31 0.46% €128.00K
≈ $149.65K
€27.54 Million
≈ $32.19 Million
-0.06pp
2013-12-31 0.52% €207.00K
≈ $242.00K
€39.54 Million
≈ $46.23 Million
+0.09pp
2012-12-31 0.43% €211.00K
≈ $246.68K
€49.06 Million
≈ $57.35 Million
-1.13pp
2011-12-31 1.56% €943.00K
≈ $1.10 Million
€60.30 Million
≈ $70.50 Million
--
pp = percentage points

About Mauna Kea Technologies SAS

PA:ALMKT France Medical Devices
Market Cap
$34.81 Million
€29.78 Million EUR
Market Cap Rank
#23917 Global
#382 in France
Share Price
€0.16
Change (1 day)
+0.65%
52-Week Range
€0.07 - €0.22
All Time High
€5.37
About

Mauna Kea Technologies SA manufactures and sells medical devices in Europe and internationally. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables unique in vivo cellular visualization, allowing doctors to monitor disease evolution over time, evaluate… Read more